ArticleNeurology international2021
Clinical Onset and Multiple Sclerosis Relapse after SARS-CoV-2 Infection.
Article in Neurology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- COVID-19 and the risk of CNS demyelinating diseases: A systematic review.Frontiers in neurology · 2022Pooled it
- Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».Reviews in medical virology · 2026Review
- Infectious Agents in Multiple Sclerosis: Viral Triggers, Antibody-Mediated Autoimmunity, and Parasitic Immunomodulation.Biomolecules · 2026Review
- Article
- Review
- Neurological Adverse Reactions to SARS-CoV-2 Vaccines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Review
- Immunopathogenesis of viral infections in neurological autoimmune disease.BMC neurology · 2023Review
- COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.Medicina clinica (English ed.) · 2023Article
- COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.Medicina clinica · 2023Article
- COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.European journal of neurology · 2022Article
- Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.Biomedicines · 2022Review
- Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.Neurology international · 2022Review
- Multiple sclerosis patients' response to COVID-19 pandemic and vaccination in Egypt.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Article
- CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review.Frontiers in neurology · 2022Article
- Frequency of Neurological Diseases After COVID-19, Influenza A/B and Bacterial Pneumonia.Frontiers in neurology · 2022Article
- The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with several neurological disorders including headache, facial palsy, encephalitis, stroke, demyelinating disorders. The present report will discuss cases of multiple sclerosis (MS) onset and relapse both beginning early after SARS-CoV-2 infection. In both cases, magnetic resonance imaging (MRI) showed widespread bilateral subcortical and periventricular active lesions. Serum IgG against SARS-CoV-2 Spike antigens confirmed seroconversion with titers that are considered not definitely protective against possible reinfection. We hypothesize that SARS-CoV-2 infection, as previously reported for other viruses, could drive an active inflammatory response that can contribute either to the onset of MS or its relapse. The presented data further support the importance of vaccination in individuals with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.